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ABSTRACT
Objective: This study was aimed to determine the prevalence of drug‑related 
problems (DRPs), identify the most common drugs, and drug classes involved in DRPs as 
well as associated factors with the occurrence of DRPs.
Methods: A prospective cross‑sectional study was conducted on 225 patients admitted to 
medical wards of Tikur Anbessa Specialized Hospital, Addis Ababa from March to June 2014. Data 
regarding patient characteristics, medications, diagnosis, length of hospitalization, investigation, 
and laboratory results were collected using data abstraction forms through review of patients’ 
medical card and medication charts. Identified DRPs were recorded and classified using DRP 
registration forms. The possible intervention measures for the identified DRPs were proposed 
and communicated to either the physician or the patient. Data were entered into Epi Info 
7 and analyzed using SPSS version 21 (IBM Corp. Released 2012, Armonk, NY: IBM Corp).
Findings: DRPs were found in 52% of study subjects. A drug‑drug interaction (48% of all DRPs) 
was the most common DRP followed by adverse drug reaction (23%). Anti‑infectives and 
gastrointestinal medicines were commonly involved in DRPs. Drugs with the highest drug 
risk ratio were gentamycin, warfarin, nifedipine, and cimetidine. The number of drugs taken 
by the patient per day is an important risk factor for DRPs.
Conclusion: DRPs are common among medical ward patients. Polypharmacy has a significant 
association with the occurrence of DRP. Drugs such as gentamycin, warfarin, nifedipine, and 
cimetidine have the highest probability of causing DRP. So, patients who are taking either 
of these drugs or polypharmacy should be closely assessed for identification and timely 
correction of DRPs.
Keywords: Drug‑related problem; medical wards; polypharmacy; Tikur Anbessa 
specialized hospital
INTRODUCTION
In the case of most diseases, drug therapy will 
enhance health‑related quality of life. However, 
inappropriate use of drugs may be harmful and lead 
to drug therapy problems.[1] In order to achieve a 
quality health care service inappropriate use of drugs 
that potentially lead to problems should be identified 
and corrected. Drug‑related problems (DRPs) are 
defined as events or circumstances involving drug 
therapy that actually or potentially interfere with 
desired health outcomes.[2]
An infinite number of DRPs exist because of the 
rapidly expanding array of drug products available, 
the growing number of diseases being recognized 
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and diagnosed, and the growing number of 
patients entering the health care system. All patient 
problems involving medications can be grouped 
into one of the seven types of DRPs. These include 
unnecessary drug therapy, the need for additional 
drug therapy, ineffective drug, dosage too low, 
adverse drug reaction (ADR), dosage too high, and 
noncompliance.[3]
DRPs may lead to reduced quality of life, increased 
hospital stay, increased overall health care cost and 
even increases the risk of morbidity and mortality.[4] 
More people die of inappropriate drug treatment than 
from breast cancer, acquired immune deficiency 
syndrome, and traffic accidents altogether.[5] An 
Institute of Medicine report estimated that between 
44,000 and 98,000 people in the U.S hospitals die 
each year because of medical errors.[5] It is estimated 
that the annual cost of drug‑related morbidity and 
mortality is nearly 177 billion dollars in the United 
States. Twice as much money is used to solve 
DRPs and adverse drug events than on the drug 
themselves.[6]
Identification and intervention on actual and potential 
DRPs, along with awareness of drugs carrying a 
high‑risk for DRPs, are important elements of drug 
therapy and may contribute to diminish drug‑related 
morbidity and mortality. The objective of this study 
was to assess DRPs in medical wards of Tikur Anbessa 
Specialized Hospital (TASH). The findings of this 
study might also help in influencing the development 
of appropriate policies, plans, and intervention 
programs for the prevention and management of 
DRPs. This in turn, might improve the quality of care 
for patients admitted to hospitals.
METHODS
This prospective cross‑sectional study was conducted 
in the medical wards of TASH, Addis Ababa, Ethiopia 
from March 15, 2014, to June 15, 2014. The hospital 
has more than 600 beds and gives diagnostic and 
treatment service for about 370,000–400,000 patients 
per year.[7] Two hundred twenty‑five patients were 
included in the study by using simple random 
sampling method. Patients admitted to intensive care 
unit, patients with <48 h length of stay and those 
who refused to participate were excluded from the 
study.
Relevant information about each patient such as 
patient characteristics, physical examination, laboratory 
results, current medications, comorbidities, length 
of hospitalization, and relevant previous medical, 
and medication histories were recorded using data 
abstraction format through reviewing patients’ 
medical cards and medication charts. Supplementary 
information and clarifications on some patient’s medical 
information were obtained through discussion with the 
patient and the physician. Taking 5–9 drugs/day were 
considered as minor polypharmacy and 10 or more 
drugs were considered as major polypharmacy.[8,9]
Data were collected, using a structured format, 
by two pharmacists who had basic knowledge on 
pharmaceutical care services who were instructed on 
how to obtain data from patient cards and medication 
charts and on how to approach the patients and 
health care professionals. Then the collected data 
were given to the authors of this research daily and 
we cheeked the appropriateness of drug therapy 
using updated references such as  Medscape (WebMD, 
LLC), UpToDate® (version 21.2, Wolters Kluwer, 
Netherlands), Epocrates® (Epocrates, Inc., San 
Francisco) and Micromedex® (Micromedex 2.0.,Truven 
Health Analytics Inc.) in order to determine the 
presence of DRP. Medscape drug interaction checker 
was used to identify drug‑drug interactions. If DRP 
was identified it was recorded and classified using 
DRP registration format (taken from Cipolle et al., 2004 
with modification).[3] Then the possible intervention 
measures were proposed and communicated to either 
the internist/resident/senior physician or the patient in 
order to resolve or prevent DRPs.
The data collection process was supervised, all 
filled DRP registration formats, and data abstraction 
formats were reviewed and cheeked for their 
completeness every day. After data was checked for 
completeness, it was edited, cleaned, and analyzed. 
The collected data were entered into Epi Info 7 
software version 7.1.4 (Centers for Disease Control 
and Prevention, Atlanta, GA) and analyzed using 
IBM SPSS statistics for Windows version 21 (IBM 
Corp. Released 2012, Armonk, NY: IBM Corp). 
Cross‑tabulation was used in the bivariate analysis. 
A test of association was done using binary and 
multiple logistic regressions. P < 0.05 was considered 
significant. Drug risk ratio (frequency of involvement 
in DRP divided by the frequency of prescription) was 
used to identify drugs that were prone to create DRP. 
Descriptive statistics was used to characterize DRPs. 
Results of the study were organized in the form of 
frequencies and percentages.
Letter of ethical clearance was obtained from the 
Ethical Review Committee of Addis Ababa University. 
Verbal consent from a patient was requested to extract 
data from patients’ medical card and medication 
charts. Privacy and confidentiality were ensured 
throughout the study. Thus, name and address of the 
patient was not recorded in the DRP registration and 
data abstraction forms.
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RESULTS
A total of 225 patients were included in the study, 
of which 114 (50.7%) were males. The mean age was 
39.1 years with the maximum number of patients 
being in the age group of 25–39 years. The majority 
of the patients (122 cases, 54.2%) were found to have 
one to two comorbidities. Only 18 (8%) of the study 
subjects were without any comorbid condition. A total 
of 1729 medications were prescribed. An average 
number of drugs per day for a patient were 7.7. 
The majority of the study subjects (112 cases, 49.8%) 
received 5–9 drugs per day. Patients’ demographic 
characteristics along with other factors that may 
influence DRPs such as number of comorbidities, 
length of hospital stay, and an average number of 
drugs received per day are shown in Table 1.
The disease distribution of the study subjects showed 
a higher incidence of infections (37.9%) followed by 
cardiovascular diseases (21.1%), malignancies (8.1%), 
electrolyte abnormalities (7.5%), and others (25.4%). 
Commonly prescribed drug classes in the study 
subjects were anti‑infectives (629), central nervous 
system drugs (294), gastrointestinal medicine (244), 
and cardiovascular drugs (171).
DRPs were found in 52% of the study subjects. A total 
of 152 DRPs were identified from 117 patients during 
the study period, in which, one DRP was identified 
in 82 (70.1%) patients, 2 DRPS in 31 (26.5%) patients, 
and more than 2 DRPs in 4 (3.4%) patients. Average 
number of DRP per patient was 0.68.
Drug interaction was the most common 
DRP (73 [48%] of all DRPs) followed by ADR (23%). 
Of the 17 DRPs classified as need for additional 
drug therapy, 9 (52.9%) were because of untreated 
medical condition, and 7 (41.2%) were due to need for 
prophylaxis therapy to reduce the risk of developing 
a new condition. The type and number of DRPs 
identified were characterized as shown in Table 2.
A total of 64 drugs were involved in different types 
of DRPs. Among these, the most frequently involved 
drugs in DRPs were cimetidine (36), tramadol (20), 
heparin (18), warfarin (16), ceftriaxone (12), 
prednisolone (11), and cotrimoxazol (10). Gentamycin, 
warfarin, nifedipine, cimetidine, simvastatin, 
prednisolone, digoxin, and pethidine were drugs with 
the highest drug risk ratio. These drugs had a risk ratio 
of above 0.33 which indicates that DRP may occur 
in more than one‑third of the times these drugs are 
used. Figure 1 shows frequency and drug risk ratio of 
commonly used drugs which were involved in DRP.
Appropriate intervention, measures were taken to 
correct the identified DRPs. The most commonly 
Table 1: Demographic details and clinical 
characteristics of the study subjects
Demographic and clinical 
characteristics of patients
Category n (%) Mean±SD 
(range)
Sex Male 114 (50.7)
Female 111 (49.3)
Age group (years) 14‑24 52 (23.1) 39.1±17.9 
(14‑85)25‑39 77 (34.2)
40‑64 63 (28.0)
≥65 33 (14.7)
Hospital stay (days) <7 83 (36.9) 10.8±7.4 
(3‑49)≥7 142 (63.1)
Number of comorbidities 0 18 (8.0) 2.2±1.4 
(1‑8)1‑2 122 (54.2)
3‑4 75 (33.3)
≥5 10 (4.4)
Average number of drugs 
received per day
<5 51 (22.7) 7.7±3.7 
(1‑15)5‑9 112 (49.8)
≥10 62 (27.6)
SD=Standard deviation
Table 2: Types of DRPs identified
DRP Category Number of DRPs Percentage of total DRPs
Drug interaction 73 48.0
Adverse drug reaction 35 23.0
Need for additional drug therapy Untreated medical condition 9 11.6
Need for prophylaxis therapy 7
Need for additive/synergetic effect 1
Inappropriate dose Low dose 6 10.4
High dose 2
Inappropriate frequency 8
Unnecessary drug therapy No indication 3 4.5
Duplication 4
Ineffective drug Not the most effective 1 2.5
Refractory to the drug therapy 2
Inappropriate dosage form 1
Total 152 100
DRPs=Drug‑related problems
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applied intervention was informing the physicians to 
monitor for the adverse effect of a drug (69) which 
may occur due to a potential drug‑drug interaction or 
potential ADR because of risk factors in a patient such 
as renal failure, history of allergy, and comorbidity. 
The rest of the interventions were as following: To 
discontinue the drug (33), to change the frequency of 
administration (24), to do laboratory monitoring (16), 
to change the dose (13), to change the drug (9), and to 
monitor for the drug’s effectiveness (4).
The identification of risk factors for DRPs may be 
helpful in finding patients at risk. These patients 
can then be given special attention, with the hope of 
avoiding overt DRPs. Sex, age, the average number 
of drugs per day, length of hospital stay, and number 
of comorbidities were analyzed to determine whether 
they could predict the occurrence of DRPs or not. The 
average number of drugs taken by the patient per 
day was shown to be a risk factor for the occurrence 
of DRPs while age, sex, length of hospital stay, and 
number of comorbidities were not. As shown in 
Table 3, patients who took an average of 5–9 drugs 
per day (minor polypharmacy) are 2 times more 
likely to develop DRPs as compared to patients who 
took <5 drugs per day while those taking more than 
10 drugs per day (major polypharmacy) are 3.1 times 
more prone in developing DRP.
DISCUSSION
The goal of drug therapy is to achieve defined 
therapeutic outcomes and improve the patient’s 
quality of life while minimizing patient risk. 
However, inappropriate use of drugs during disease 
management may lead to drug therapy problems. 
This study was carried out to assess DRPs in medical 
inpatients of one of a tertiary care teaching hospital in 
Ethiopia.
This study showed that 52% of patients admitted to the 
medical wards of TASH had DRPs. This result is lower 
than what was found in Jimma, Ethiopia (73.5%).[10] 
The lower rate of DRP in this study might be because 
the data collection of the study in Jimma were done 
at 2011 when clinical pharmacists were not involved 
in the ward‑based activities, while in the period 
and setting of the current study, pharmacists were 
involved in the ward activities. The study in Malaysia 
also found a prevalence of 90.5%.[11]
The most frequently encountered DRPs in the present 
study were drug‑drug interaction. Similar studies 
from different countries showed drug‑drug interaction 
was among the top ranking types of DRPs.[8,12‑14] Even 
though the majority of drug‑drug interactions in our 
Table 3: Associated factors for the occurrence of DRPs
Variables Category DRPs (%) COR (95% CI) AOR (95% CI)
No Yes
Sex Female 55 (50.9) 56 (47.9) 1.00 1.00
Male 53 (49.1) 61 (52.1) 1.13 (0.670‑1.908) 1.07 (0.63‑1.83)
Age 14‑24 27 (25.0) 25 (21.4) 1.00 1.00
25‑39 36 (33.3) 41 (35.0) 1.23 (0.608‑2.488) 1.69 (0.69‑4.09)
40‑64 31 (28.7) 32 (27.4) 1.12 (0.535‑2.324) 1.39 (0.59‑3.24)
≥65 14 (13.0) 19 (16.2) 1.47 (0.609‑3.530) 1.56 (0.64‑3.84)
Hospital stay <7 days 45 (41.7) 38 (32.5) 1.00 1.00
≥7 days 63 (58.3) 79 (67.5) 1.49 (0.862‑2.559) 1.28 (0.73‑2.24)
Number of comorbidities 0 9 (8.3) 9 (7.7) 1.00 1.00
1‑2 63 (58.3) 59 (50.4) 0.937 (0.348‑2.520) 1.71 (0.35‑8.36)
3‑4 30 (27.8) 45 (38.5) 1.500 (0.534‑4.214) 2.32 (0.60‑8.99)
≥5 6 (5.6) 4 (3.4) 0.667 (0.139‑3.194) 1.52 (0.41‑5.71)
Number of drugs <5 33 (30.6) 18 (15.4) 1.00 1.00
5‑9 53 (49.1) 59 (50.4) 2.041 (1.030‑4.043) 2.02 (1.14‑3.31)*
≥10 22 (20.4) 40 (34.2) 3.333 (1.536‑7.235) 3.13 (1.43‑6.89)*
*Statistically significant. COR=Crude odds ratio, AOR=Adjusted odds ratio, CI=Confidence interval, DRPs=Drug‑related problems
Figure 1: Frequency and drug risk ratio of commonly used 
drugs involved in drug‑related problems
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study were only potential, there are some interactions 
that had resulted in significant adverse events like 
bleeding, raised international normalized ratio (INR), 
hypoglycemia, and constipation. The most common 
intervention measure given for this class of DRP was 
informing the physicians to monitor the patient for 
serious adverse events. In addition, monitoring for 
the effectiveness of some drugs and limiting the daily 
dose of a drug (e.g., paracetamol dose not more than 
2 g/day when given with imatinib or rifampin) were 
taken as intervention measures. As drug interactions 
can affect patient’s clinical outcome, quality of life, 
as well as contribute to unnecessary healthcare 
cost, the high prevalence rate (48% of all the DRPs) 
in this study would make this an important area 
requiring future focus of pharmacists on reviewing 
patients’ medication charts and checking for potential 
drug‑drug interactions.
The second most common DRP identified in 
this study was ADR (23%). This was in close 
proximity with the result of Harvard Medical 
Practice Study showing up to 20% of hospitalized 
patients experiencing at least one ADR during their 
hospital stay.[15] Some of the adverse drug events 
identified in this study were bleeding/increased 
INR due to warfarin; hepatotoxicity due to 
anti‑tuberculosis (TB) medications, propylthiouracil, 
and cancer chemotherapy; allergic reaction due to 
cotrimoxazole, vancomycin, and furosemide; gastritis 
due to acetylsalicylic acid (ASA), cotrimoxazole and 
anti‑TB drugs; nephrotoxicity due to vancomycin and 
tenofovir; atrioventricular block due to digoxin and 
megaloblastic anemia due to phenobarbital.
Among patients who needed additional drug 
therapy, 29.4% were those who needed potassium 
chloride for treating hypokalemia and those who 
needed stress ulcer prophylaxis. There were also 
patients who needed pyridoxine, cotrimoxazole, 
and anti‑convulsants as prophylaxis for neuropathy, 
Pneumocystis carinii pneumonia, and seizure, 
respectively. Ineffective drug use (2.6%) was less 
frequently occurring DRP in this study. This result 
is in close agreement with a study in Jimma, which 
showed ineffective drug therapy (2.7%) as the less 
frequently occurring DRP among all the DRPs 
identified.[16]
It is necessary to be aware of those drugs with the 
highest drug risk ratio (high rate of causing DRP) 
since these are drugs most frequently expose the 
patient to DRP when taking them. In this study, 
gentamycin, warfarin, nifedipine, cimetidine, 
simvastatin, prednisolone, digoxin, and pethidine 
were drugs with the highest drug risk ratio. 
Similarly, the study in Norway mentions warfarin, 
prednisolone, and digoxin among drugs with the 
high‑risk ratio.[17]
Cimetidine was one of the frequently prescribed 
drugs in medical wards. It has a higher drug 
risk ratio because of its frequent involvement in 
interaction with various drugs such as tramadol, 
prednisolone, dexamethasone, warfarin, fluconazole, 
cotrimoxazole, pethidine, hydrocortisone, diazepam, 
codeine, nimodipine, simvastatin, and digoxin. The 
mechanism of interaction of cimetidine with these 
drugs was either by inhibiting cytochrome P450 
enzyme or by increasing gastric pH. Involving in 
drug interaction was also a very common reason 
for being a high‑risk drug for digoxin, pethidine, 
and simvastatin. Gentamycin was found to cause 
nephrotoxicity because of its interaction with 
furosemide. In 42% of patients who took warfarin 
there was either an actual ADR (bleeding) or raised 
INR, or serious drug interaction with other drugs 
like cimetidine, ceftriaxone, cotrimoxazole, heparin, 
ciprofloxacin, ASA, fluconazole, and azithromycin. 
Nifedipine was involved in dose‑related problem and 
drug interaction with phenytoin and simvastatin.
In the attempt to identify risk factors, the result of 
this study supported published findings that the 
number of drugs taken by a patient is an important 
risk factor for DRPs, but sex and age did not have 
significant correlation with the occurrence of DRP. 
The number of medications used was found to be 
a risk factor for increasing DRPs by a number of 
studies.[8,18‑21] However, sex and age were not found 
to affect DRPs.[8,19,20,22] In our study, length of hospital 
stay and a number of comorbidities were not found 
to significantly affect the occurrence of DRP. Similarly, 
the study in Jimma by Tigabu et al. did not show a 
significant association between the likelihood of DRP 
occurrence and length of hospital stay or a number of 
comorbidity.[10]
In this study, drug therapy problems related to 
adherence to the prescribed medications were not 
addressed because of time and budget constraint. 
The result of the study may not be generalized to 
all hospitals because it was a single‑centered study 
conducted in a hospital serving referred patients who 
have severe illnesses and more comorbidity. So we 
suggest further multi‑centered studies to be done.
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